Introduction
irregular uterine hemorrhage, endometrial cancer, endometriosis, hyperplasia, DIE, cancer, endometrial hyperplasia, amenorrhea, weight gain, acne
ENDOMETRIAL CANCER, ENDOMETRIOSIS, HYPERPLASIA, CELLULAR ATYPIA, ENDOMETRIAL HYPERPLASIA, CANCER, ENDOMETRIAL HYPERPLASIA, ACNE, CYTOLOGIC ATYPIA
Endometrial hyperplasia, which may lead to endometrial cancer or coexist with it, is characterized by an excessive growth of the endometrial glands [Although this ailment is often detected during the postmenopausal stage, it may occur at any age as long as the person is exposed to estrogen. The most significant risk factor for the development of endometrial cancer from hyperplasia is hyperplasia with cellular atypia. The most prevalent indication of endometrial hyperplasia is irregular uterine hemorrhage [In 80% of instances, simple hyperplasia that is left untreated heals on its own; in 19% of cases, it persists; and in 1% of cases, it turns into cancer. However, the chance of developing cancer rises when cytologic atypia is present [The progestin's mode of action for treating hyperplasia involves pseudo-decidualization, a decrease in the number of endometrial glands, and their anti-estrogenic activities [Progestin is proven to be useful in treating endometrial hyperplasia, however the side effects of progestin medications, particularly older second-generation medications, include weight gain, mood changes, acne, amenorrhea, and negative vascular consequences. [Dienogest (DIE), a fourth-class oral progestin from a new generation, combines the pharmacologic characteristics of progestin derivatives with those of 19-norprogestins. It has potent progestogenic impacts without androgenic, mineralocorticoid, or glucocorticoid activities, making it particularly useful for the cure of endometriosis [Our research compares the efficacy of DIE and norethisterone acetate (NETA) regimens for treating EH without atypia.